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2. We performed a systematic literature search on long-term treatment 
effects, risks and monitoring of antipsychotic medication in schizophrenia.
Results: 1. In NFBC1966 in midlife, higher lifetime doses of antipsychot-
ics were associated with alterations in brain morphometry, poorer neuro-
cognition, and poorer clinical outcomes. Clinical follow-up was inadequate 
even in half  of the schizophrenia cases. In therapeutic community cohort, 
maximal development of psychosocial care reduced the mean dose of 
antipsychotics in acute psychosis ward from 370 mg/day as chlorproma-
zine equivalents into 160 mg/day. 2. In the literature review, three main cor-
nerstones in the high quality longitudinal use of antipsychotic medication 
were: a) high, evidence-based pharmacological quality, b) optimal adjuvant 
psychosocial therapies, c) sophisticated long-term prescription, monitor-
ing and follow-up practices to minimize nonadherence and psychiatric and 
somatic failures.
In sum, antipsychotics are effective for acute and mid-term psychosis in 
prevention of relapses and excess mortality. Long term antipsychotic use 
especially in high doses may include major iatrogenic harms, as also poorly 
monitored withholding or discontinuing. When aiming for an optimal 
benefit-risk ratio and for balancing symptomatic, functional and somatic 
outcomes, the goal is to aim for lower ranges of effective dosing, as well 
as choosing an appropriate antipsychotic agent that causes minimal side 
effects, and to combine adjuvant psychosocial interventions in the treat-
ment. The often recommended personalized smallest effective dose is not 
so simple but still a realistic strategy in current relapse prevention practices, 
where doses often are too large for safety reasons.
Discussion: Cohort-based register studies are useful in examining long-term 
medication effects although they contain a risk of residual confounding 
due to their observational design. However, randomized controlled trials in 
long, over 3–7 years of follow-up, are unrealistic.
The systematic literature review demonstrates major open or conflict-
ing questions in risk-benefit ratio related to long-term outcomes. Non-
adherence and attrition are key problems in sustained antipsychotic 
medication. Standardized prescription and monitoring practices (not so 
much studied) might improve medication adherence and also outcomes. 
Current clinical guidelines advise us based on studies from first years of 
schizophrenia. There are only few and weak patient-level predictors of suc-
cessful tapering and discontinuation of antipsychotic medication.
In the future, clinical follow-up of medication can be improved by struc-
tured follow-up and planned continuity. Life span view of antipsychotic 
medication stresses careful documentation of doses, responses and harms, 
longitudinal planning and realization of medication as part of the whole 
treatment program, as well as individualized and tailored selection, dos-
ing (dose as low as possible or minimal effective dose) and follow-up by a 
well-trained team.
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Background: The primary aim of this study was to generate neurobiological 
evidence regarding the impact of dopaminergic and glutamatergic neuro-
transmission on reasoning biases related to delusional ideation in patients 
with schizophrenia associated with impaired processing of sensory informa-
tion. The proposed respective roles of these neurotransmitter systems have 
been encapsulated in the so-called dopamine- and glutamate-hypotheses of 
schizophrenia. From a behavioural perspective both reduced glutamate and 
enhanced dopamine levels are currently discussed as critical contributing 
factors to generate aberrant beliefs (glutamate) during information sam-
pling and to generate confidence or expected precision (dopamine) during 
action selection. Hence, by modulating levels of glutamate and dopamine 
in the brain we hypothesized to induce reported impairments of patients 
with schizophrenia related todelusional ideation.
Methods: The study consisted of three aligned experiments: In the first two 
experiments a prospective interventional drug study was conducted with 
n=192 participants employing a randomized, placebo-controlled, double-
blinded design on two parallel testing-groups, receiving either dopami-
nergic or glutamatergic neuromodulators: Experiment I: either 2.5mg 
haloperidol (D1/D2-receptor antagonist; HAL), 2.5mg bromocriptine 
(D2-receptor agonist; BRO), or placebo (PLC-1). Experiment II: either 
120mg Dextromethorphan (NMDA-receptor antagonist, DXM), 250mg 
D-Cycloserine (NMDA-receptor agonist, CYC), or placebo (PLC-2). In the 
third experiment n=45 patients with schizophrenia (SZ) and n=45 healthy 
control participants (HC) matched for gender, age and IQ were investi-
gated. All experiments employed a computerized (Matlab, Cogent) version 
of the Beadstask (Huq, Garety et al. 1988). In total participants processes 
60 Beadstask trials subdivided into three levels of difficulty: (I) easy trials 
with a bias of 80–90% for one predominant bead color in a sequence, (II) 
difficult trials (60–70% bias), and (III) ambiguous trials (no bias, 50% likeli-
hood). Additionally, the task consisted of three parts that were presented 
in a fixed order: an easy draws-to-decision condition, an easy probability 
estimates condition, and a difficult draws-to-decision condition.
Results: In accordance with foregoing studies, SZ patients showed signifi-
cantly less draws to decision compared to HC (all p≤0.038). Explorative 
analysis across experimental conditions further revealed no significant 
differences for participants receiving DXM (NMDA-receptor antagonist) 
compared SZ patients (all p≥0.090), but obtained less draws to decision in 
the DXM group than all other groups. Whereas following HAL interven-
tion the number of draws increased significantly compared to any other 
experimental group (all p≤0.048). Analyzing the probability estimates 
condition we quantified changes of probability estimates on an individual 
subject level whenever there was a change of bead color in a sequence (so 
called disconfirmatory evidence score, DES). In case of easy and difficult 
trial types we observed significantly higher DES scores in participants with 
SZ compared to HC (p≤0.003) and again obtained no differences between 
SZ and DXM (p=0.037).
Discussion: Our findings are supportive for a hypothesized relationship 
between neurotransmitter state alterations of glutamate and dopamine in 
patients with schizophrenia and the delusional ideation. Future analysis 
will focus on developing a computational behavioral model of cognitive 
processing of the Beadstask, implementing our neurobiological findings 
in order to further disentangle the neurobiological underpinnings of delu-
sional ideation in patients with schizophrenia.
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Background: Most investigations into the pharmacology of schizophrenia 
have revolved around dopaminergic and glutamatergic neurotransmission; 
however, one neurotransmitter that has not received adequate attention is 
the cholinergic system. Indeed, several post-mortem, genetic and epide-
miologic studies link specifically the alpha7 nicotinic receptor (nAChR) to 
schizophrenia, and the potential use of alpha7 modulators as a treatment 
strategy is an active field of research. Nevertheless, studies to date have 
been limited to normal animals rather than on a validated neurodevelop-
mental model of schizophrenia. Moreover, knowledge about the differen-
tial impact of orthosteric and allosteric modulators in vivo is lacking. Thus, 
we investigated the effects of alpha7 nAChR modulation on dopamine 
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